
    
      Patients will be treated with intravenous cabazitaxel 25 mg/m2 every 3 weeks (D1=D22) for 6
      cycles.

      In absence of progression disease or unacceptable toxicity, the treatment could be continued
      until a maximum of 10 cycles.

      Disease response will be assessed every 6 weeks (i.e. every 2 cycles) clinically and by
      CT-scan.

      An interim analysis will be carried out after the inclusion of the first 10 eligible and
      assessable patients.
    
  